Prelude Therapeutics focuses on the discovery and development of targeted cancer therapies, employing a precision oncology approach. This involves identifying key driver mechanisms within cancer cells and designing small molecule therapies to selectively inhibit these targets. Research and development activities encompass preclinical studies, clinical trials, and biomarker identification to optimize patient selection and treatment response. The company's pipeline includes candidates targeting various cancer types and molecular pathways, with the goal of improving patient outcomes and addressing unmet medical needs in oncology. Technologies used include advanced molecular biology techniques, high-throughput screening, and rational drug design. This segment aims to provide personalized treatment options for cancer patients, enhancing efficacy and minimizing off-target effects.